Curasight's Rights Issue Aims to Raise DKK 100 Million
Curasight announces a significant rights issue to support its innovative cancer diagnostics and treatment platforms.
Sammanfattning
Curasight is launching a rights issue to raise approximately DKK 100 million, aiming to fund its cancer diagnostics and treatment platforms until mid-2026.
Curasight A/S, a pioneering company in cancer diagnostics and treatment, has announced a rights issue aimed at raising approximately DKK 100 million in gross proceeds. This strategic move is designed to bolster the company's financial standing, supporting its innovative theranostic approach to cancer treatment through its uTRACE® and uTREAT® platforms.
The rights issue, if fully subscribed, will provide Curasight with the necessary capital to continue its ambitious development programs. The funds are expected to cover the completion of the Phase II trial for uTRACE® in prostate cancer and the Phase I trial for uTREAT® in brain cancer, among other strategic initiatives.
CEO Ulrich Krasilnikoff expressed optimism about the future, highlighting the strategic partnership with Curium, a global leader in nuclear medicine. This partnership validates Curasight's theranostic approach and enhances its capabilities in delivering precise cancer diagnostics and treatments.
In terms of financial strategy, the rights issue is supported by significant commitments from key partners like Curium and Pentwater, alongside guarantee commitments from external investors. This robust backing underscores confidence in Curasight's innovative platforms and strategic direction.
For investors, the rights issue presents an opportunity to participate in a company at the forefront of cancer treatment innovation. Given the strong backing and strategic partnerships, the recommendation is to hold current investments in Curasight, as the potential for growth and value creation remains significant.
Källa
Sammanfattning
Curasight plans to raise approximately DKK 100 million through a Rights Issue, with final terms expected to be announced on April 24, 2025. The subscription price will be set at 65% of the theoretical ex-rights price, but not lower than the nominal share value, capped at DKK 10.24. The Rights Issue is partially covered by subscription and guarantee commitments totaling about 47% of the issue. The record date is tentatively set for May 1, 2025, with a subscription period from May 2 to May 16, 2025. Curasight has renegotiated an outstanding loan with Fenja Capital and secured a bridge loan of DKK 8 million, with warrants issued to Fenja Capital. The funds raised will support ongoing clinical trials and operational costs until mid-2026. The Rights Issue is subject to approval at an Extraordinary General Meeting on April 23, 2025. Sedermera Corporate Finance AB is coordinating the issue, and further details will be published in an information document on April 29, 2025.
